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ASSOCIATION BETWEEN DISRUPTION OF FIBRIN SHEATHS 
AND LATE ONSET OF CENTRAL VENOUS STENOSIS 
 
Nina Ni, Hamid Mojibian, Jeffrey Pollak, Michael Tal. Department of Diagnostic 
Radiology, Vascular and Interventional Radiology, Yale University School of Medicine, 
New Haven, CT 
 
This study compares the rates of central venous stenosis in patients undergoing 
hemodialysis who underwent disruption of fibrin sheath with percutaneous transluminal 
angioplasty (PTA) balloons and those who underwent over the wire catheter exchange. 
 
This study is a retrospective review of 209 PTA balloon disruption and 1,304 over the 
wire catheter exchange procedures. Approval from the Human Investigations Committee 
was obtained for this study. Up to ten year follow up was performed. A χ2 test was used 
to compare the rates of central venous stenosis after balloon disruption versus catheter 
exchange. A T-test was used to compare time to central venous stenosis development. 
 
Of the 753 patients in the study, 127 patients underwent balloon disruption of fibrin 
sheath and 626 had catheter exchange. Within the balloon disruption group, 18/127 
patients (14.2%) subsequently developed central venous stenosis, compared with 44/626 
(7.0%) in the catheter exchange group (P<0.01, χ2 test). Time to central venous stenosis 
development was approximately 3 years in both groups and not significantly different 
(1,371 and 1,010 days, P=0.20). Twenty five point two percent of patients in the balloon 
disruption group had 4 or more subsequent catheter exchanges versus 12.6% in the 
catheter exchange group (P<0.01, χ2 test). 
 
There is a possible association between PTA balloon disruption of fibrin sheath and late-
onset central venous stenosis. Since venography was not routinely performed in catheter 
exchange patients, future randomized studies are necessary to confirm these findings. 
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In the U.S., approximately 25% of hemodialysis patients use catheters for 
hemodialysis, up from 13% over ten years ago.(1, 2) It has been reported that as many as 
one in five new dialysis patients start their treatment with tunneled cuffed catheters.(3)  
Dialysis catheters are used either as temporary solutions while patients wait for fistula 
preparation or kidney transplantation, or as the sole chronic access method. 
Complications associated with dialysis access are on the rise, as patients diagnosed with 
end stage renal disease (ESRD) are increasing both in age and in the number and severity 
of co-morbidities.  
Hemodialysis patients currently have high rates of morbidity and mortality, and 
the vascular access catheters are a contributing factor to these clinical outcomes. The 
main problems associated with long-term catheterization include thrombosis, vascular 
stenosis, and infection.(4, 5) Consequently, newer catheter designs often aim to address 
these issues with innovations over existing products. 
Maintaining patients on hemodialysis catheters for the long term is suboptimal 
from both patient comfort and healthcare cost perspectives. NKF-K/DOQI guidelines 
recommend that less than 10% of chronic renal failure patients be maintained on dialysis 
catheters, due to the high rates of complications.(6) In terms of healthcare cost, the U.S. 
spends $1-1.5 billion annually on maintaining patients who use hemodialysis catheters.(7) 
However, only 10% of that is the actual cost of the dialysis catheters themselves. A large 
 2
portion of this cost goes toward the hospitalization and procedural costs necessary to 
manage post-placement complications and catheter exchange. Therefore, careful selection 
of dialysis catheters and appropriate management of these events can yield much patient 




Short term/ acute catheters 
 
In general, short term central venous catheters for hemodialysis do not have a 
Dacron retention cuff and are not tunneled.(8) While the majority of long term CVCs are 
tunneled due to their reduced complication profile, non-tunneled short term catheters are 
easier to place and remove. These catheters can be rapidly replaced by guide-wire at the 
bedside and without surgeon or radiographic guidance. Therefore, the catheter shaft must 
be rigid enough to progress through the subcutaneous tissues. They may also be 
precurved for jugular placement over the clavicle to reduced patient discomfort and 
catheter movement-related injury at the exit site.(9) 
The current standard short term catheter is a dual lumen catheter, with the venous 
port 2-3 cm distal to the arterial port to prevent recirculation.(10) Selecting between the 
two major biomaterials, polyurethane and silicone, reflects a tradeoff between ease of 
placement and blood flow. The rigid polyurethane catheter can be more easily placed 
over guidewire without a sheath. The material provides an initial stiffness upon insertion, 
but then softens when exposed to body temperature.(11)  It can also withstand high 
negative aspiration pressures, permitting adequate hemodialysis with a smaller diameter 
 3
catheter. Newer designs utilize silicone to provide a larger lumen for higher blood flow, 
reaching 400 ml/min or greater as opposed to 250 ml/min with polyurethane catheters.(10) 
However, due to the flexibility of the material, a peal-away sheath must be employed.     
The acute dialysis catheter market in the United States consists of 5 major 
catheter manufacturers:  Covidien, Arrow, Bard, Angio Dynamics, and Medcomp.    
Covidien MAHURKAR, Arrow, Bard Niagara, and MedComp Duo Flow acute dialysis 
catheters are made from polyurethane.  Other catheters, such as the Angio Dynamics 
Schon XL and Medcomp Hemocath are made from silicone and include insertion stylets 
to provide rigidity upon insertion.   
 
Chronic catheters 
According to NKF-K/DOQI guidelines, long-term tunneled cuffed catheters 
should be inserted when anticipated use is three weeks or longer.(6) These long-term 
catheters are designed to be soft so that endovascular trauma can be minimized.  A rigid 
shaft and tapered tip, which make the acute hemodialysis catheter easy to insert, also 
renders it unsuitable for long term use.  If left for a long time within the superior vena 
cava or right atrium, the rigid, sharp material could cause significant injury to the 
tissues.(12) 
Chronic hemodialysis catheters are almost always tunneled, with a bonded cuff 
for anchoring and for preventing bacterial migration. Central venous access has been 
associated with bacteremia incidences of 2-7 cases per 1,000 catheter days. However, the 
rate for untunneled catheters range from 3.8-6.5/1,000 catheter-days, and 1.6-5.5 for 
tunneled cuffed catheters.(13-17) While these retrospective studies differ in definition 
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and protocol, a meta-analysis of randomized, controlled trials by Randolph et al 
demonstrated that cuffing and tunneling of catheters reduces the risk for catheter-related 
bacteremia by 44-77%.(18) Tunneled catheters have also been shown to confer lower 
infection and hospitalization rates.(19-22)    
The chronic dialysis catheter market in the United States consists of the following 
catheter manufacturers:  Covidien, Arrow, Bard, Angio Dynamics, Medcomp, Boston 
Scientific and Spire. The majority of these chronic catheters are made from polyurethane, 
which provides an initial stiffness upon insertion, but then softens when exposed to body 
temperature.  Other catheters, such as the Covidien Permcath, Medcomp Hemo-Cath, and 
Medcomp Hemo-Flow are made of silicone.  
Historically, long-term access devices were made from medical grade silicone 
rubber.  It offered a soft, flexible material causing less damage to the intima of the vein 
on insertion. Its biocompatibility, relatively non-thrombogenic surface, and resistance to 
chemicals help increase longevity and minimize complications such as thrombosis and 
infection. The catheters are generally autoclaved or EtO gas sterilized. The softness of the 
silicone polymer also allows for a larger lumen and placement within the right atrium for 
maximum blood flows. However, due to its inherent softness, silicone catheters often 
require thicker walls prevent collapse under low pressures and avoid kinking.(23) 
Additionally, the necessity of a large diameter peel-away sheath implies a larger 
cannulation hole in the vein.  
Advances in material technology have resulted in the transition from silicone 
based dialysis catheters to the use of polyurethane. Thermoplastic polyurethanes (or melt-
processable polyurethanes) are used extensively in medical devices.  They are composed 
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of long-chain linear polymers without cross-links, which are weakly bonded at room 
temperature, but become free to slide past one another under sufficient thermal energy—
such as provided by the body.(24)  Compared with silicone catheters of the same French 
size, polyurethane catheters can have larger internal diameters without sacrificing rigidity 
outside the body and flexibility within the body. The increase in lumen diameter results 
in increased blood flow rate. The catheters are easy to insert, as they soften upon entry 
into the body. A good catheter must also have sufficient column strength, enabling it to 
advance into the body with minimal tangling. Like silicone catheters, these products are 
also biocompatible, non-thrombogenic and EtO gas sterilized. In the case of multi-lumen 
polyurethanes catheters, thin intra-lumenal walls can be constructed, which allow for the 
maximum number of lumens while maintaining a minimum outer diameter.  
Carbothane is a polyurethane/polycarbonate copolymers that affords strength for 
longevity and softness for flexibility and patient comfort. With slightly greater strength 
than polyurethane, it can afford to have thinner walls. Unlike polyurethane, copolymers 
are also resistant to iodine, peroxide, and alcohols. In the future, the majority of chronic 
catheters are expected to be constructed from copolymer materials.(23)  
In vitro and in vivo comparisons between silicone and polyurethane as catheter 
materials remain inconclusive. Animal models appear to attribute an increased infection 
risk and thromogenicity to silicone catheters over polyurethane catheters.(25, 26) It might 
be that silicone catheters have a rougher topography, and are more prone to construction 
failures because of the more difficult manufacturing process.(27) However, in a study 
comparing silicone and polyurethane CVCs inserted at the cubital fossa, neither material 
was found to be superior in thrombogenecity, platelet adhesion, or catheter occlusion 
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rate.(28) In a study of urethral catheter surface properties, there is even some evidence 
that silicone-based materials exhibit a greater ease of removal than polyurethane-based 
materials, due to greater surface lubricity.(29) Ion implantation of silicone rubber has 
been instrumental in improving silicone’s hydrophilicity and lending it resistance to 
biomaterial deposits.  Additionally, polyurethane reacts strongly to alcohol, and the only 
antibiotic ointment that can safely be used at the exit site is Neosporin. Silicone, on the 
other hand, is compatible with most ointments. 
Although catheter materials are selected to be biocompatible and hemocompatible, 
complications due to thrombosis and infection are still inevitable. To date, central access 




The use of antithrombogenic and anti-microbial surface technologies on the 
catheters is one way of reducing the likelihood of complications due to thrombosis or 
microbial colonization. In acute catheters coated with antibiotics, silver, or heparin the 
number of infections can be reduced substantially. Heparin-coated catheters, in particular, 
may confer the additional benefit of cost-effectiveness.(30) 
Heparin-coated catheters presents a way to decrease infection rate without the 
risks of systemic antibiotic exposure or bacterial resistance. Heparin exhibits 
anticoagulant activity via interaction with the plasma protein antithrombin as well as 
some electrostatic repulsion of charged platelets. Therefore, it can reduce bacterial 
trapping within fibrin clots and sheaths.(31) Hydrophobic and electrostatic interactions 
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also decrease direct bacterial adhesion onto catheter polymer. Heparin immobilized on a 
plastic surface has been reported to diminish both fibronectin deposition and to decrease 
bacterial adherence in vitro.(31, 32)  
Several studies have demonstrated the safety and efficacy of using heaparin-
bonded catheters in vivo. In blinded, prospective studies of critically ill children requiring 
femoral or central venous catheterization, two groups of researchers have found that 
heparin-bonded catheters are associated with significantly fewer thrombotic 
complications and a reduced incidence of infection.(33, 34) The major prospective 
clinical study of heparin-bonded central venous catheters is a 1996 study by Appelgren et 
al.(31) In vitro, coagulase-negative Staphylococci adhered less to heparinized catheters 
than to control catheters. The clinical study, while small (32 patients), showed that 
heparinized catheters are associated with a significant decrease in catheter-associated 
bacteremia (26% vs. 0%, p = .047) and bacterial colonization (31% vs. 74%, p = .03).  
Covidien offers the Tal Palindrome Emerald hemodialysis catheter, which 
incorporates a non-eluting heparin coating technology developed by BioInteractions Ltd.  
Through in vitro and in vivo testing, this coating has been shown to reduce platelet 
adhesion and thrombus accumulation on the catheter surface. The coating design adopts a 
multifaceted approach to hemocompatability, by containing functional groups that have 
demonstrated performance in hydrophilicity, minimizing platelet adhesion, non-
thrombogenecity and anti-thrombogenecity.(35)  
Spire Biomedical Inc. offers a heparin coated hemodialysis catheter, marketed as 
the Decathlon Gold, which includes the Carmeda BioActive Surface (CBAS) coating.  
The CBAS coating technology has also been shown to reduce platelet adhesion and 
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thrombus accumulation on the catheter surface through in vitro and in vivo testing.  In 
addressing one of the key problems related to systemic anticoagulation with heparin, the 
CBAS “end-point” attachment method provides a stable heparin-biomaterial bond that 
allows for locally-expressed heparin activity at the catheter surface.(36) 
The use of other coating materials such as silver and antibiotics has also been 
promising. While results have been significant for acute use, studies on chronic 
hemodialysis catheters have yielded inconclusive results. For silver coated catheters, 
Trerotola et al. showed no statistically significant difference in infection rate between the 
47 patients in the treatment group versus the 44 patients in the control group. Two of the 
silver-coated catheters were also prematurely removed due to silver allergy.(37) However, 
data from a more recent large-scale prospective study reveals that silver coating can have 
an anti-microbial benefit: in long-term coated catheters, bacterial colonization was 
observed on 11% of catheter tips, versus 44% for uncoated catheters.(38) The key 
difficulty with coating chronic hemodialysis catheters is that the bonded substance can 
disappear over time, rendering them ineffective over long periods.(39) 
Covidien also offers the Tal Palindrome Ruby® which incorporates an anti-
microbial silver ion sleeve bonded between the hub and the cuff.  This sleeve delivers 
silver ions to the surface of the catheter to reduce microbial colonization on the catheter 
surface within the tunnel track.  In vitro testing with clinical isolates of Staphylococcus 
aureus, Coagulase-negative staphylococcus, Candida albicans, and Escherichia coli has 
shown a 99.2%-99.999% (2.1-5.5log10) reduction in microbial colonization.(35)  
Covidien is also offering a chronic dialysis catheter that provides both anti-
thrombogenic and anti-microbial technologies on one catheter, the Tal Palindrome 
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Sapphire®. The catheter combines the heparin coating technology with an anti-microbial 
silver ion subcutaneous sleeve.(40)  
The Bard Hemosplit® and Hemostar® catheters include the BioBloc coating, 
which is an eluting silver sulfadiazine technology intended to reduce bacterial adhesion 
on the catheter by 99.9% in the catheter tunnel for a period of twenty-one days.  The 
company has performed in vitro tests against Staphylococcus epidermidis, 
Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, Enterococcus 
faecalis, and Escherichia coli.(41)   
Antibiotic-impregnated catheters have also shown significant anti-infective 
benefit. Antibiotics, most commonly a combination of minocycline and rifampicin, coat 
both the inner and outer surfaces of the catheter. There have been many clinical trials of 
coated catheters compared with uncoated controls or head-to-head against other coatings. 
In a 2008 review of 37 of these randomized controlled trials involving 11,586 patients, 
Gilbert and Harden conclude that heparin-coated and antibiotic-impregnated central 
venous catheters lead to significant reductions in catheter related bacteremia, while no 
strong evidence exists for antiseptic cathethers (coated with chlorhexidine and silver 
sulphadiazine, or sliver-impregnated).(42) All relative risk calculations from the studies 
indicate a strong positive effect of antibiotic coating on the rate of catheter-related 
bloodstream infection. However, there is also some evidence of antibiotic resistance from 
in-vitro studies. Additionally, only two major prospective studies involve average 
catheter use over two weeks, raising the question of antibiotic impregnation longevity.(43, 
44) 
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Recently, Angiotech received 510k clearance on a central venous catheter coated 
with 5-fluorouracil (5-FU).  Since 5-FU is not used routinely in hospitals as an antibiotic, 
the drug has the unique ability of inhibiting bacterial growth and metabolic functions of 
most microorganisms while reducing the risk for creating resistant strains.  Coating a 
catheter with a minimal amount of 5-FU renders the surface hostile for microbes, without 
significant changes in patient tolerability profile.(45) The data from Angiotech’s 960 
patient clinical trial comparing its 5-FU CVC with a chlorhexidine/silver sulfadiazine 
(CH-SS) coated CVC shows non-inferiority. However, the 5-FU device appears to be 
superior in the nature of the colonizations and infections: while the 5-FU coated CVCs 
were colonized with S. epidermis and other common contaminants, the catheters with 
CH-SS were also colonized with methicillin-resistant S. aureus, E. coli, K. pneumoniae, P. 
mirabilis, S. marcescens, and A. baumannii.(46) 
 
Catheter lumen and tip design 
  
Several lumen designs have emerged over the years. The earliest tunneled cuffed 
catheter, the PermCath by Quinton, was a large, oval shape with two separate lumens. 
Subsequent improvements have included a round lumen with a central wall, two separate 
single lumen catheters for differential placement of the inflow and outflow catheter 
(Tesio, MedComp), and fusion of the two single lumens at a distal point along their 
length for easier insertion (Ash Catheter, Medcomp).(10)  
Two key prospective randomized studies have demonstrated that while double 
lumen and two single lumen catheters do not lead to appreciable differences in survival or 
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infection rate, double lumen catheters should be chosen for their ease of use.(27, 47) In a 
randomized trial of 64 patients, Trerotola et al concluded that the Ash-split catheter and 
Opti-flow dual lumen catheter had no differences in catheter-related bacteremia and late 
flow problems.(27)  Richard et al compared 38 Ash-split, 39 Opti-flow, and 36 Tesio 
catheters.(47) The Tesio catheter (two single lumens) required a significantly longer 
period of time for insertion (mean 42 min versus 29-30 min for the other catheters), 
leading to more insertion complications. However, mean flow rates and catheter-related 
infections were not significantly different. These studies demonstrate that in the absence 
of benefits in post-insertion complications, ease of use may better govern lumen choice. 
Commonly used long-term hemodialysis catheters have a staggered tip design, 
meaning that the outflow tip extends several centimeters (typically a minimum of 2.5 cm) 
beyond the inflow tip, to prevent recirculation. Another common traditional design is the 
split tip or dual catheter design. The original split tip catheter is the Ash Split, designed 
by Dr. Ash and marketed by Medcomp. This catheter has many side holes, thought to 
facilitate good function. A more recent version of the split tip catheter is the Centros® 
catheter, also designed by Dr. Ash. The rational behind eliminating the side holes in this 
model is that the lack of irregular surfaces surrounding the side holes would improve 
catheter function and survival, and may also reduce infections.  
Despite the evolution of tip design, there are few studies on the influence of tip 
geometry on patient outcomes. The Richard et al study comparing three different tip 
designs (Tesio dual catheter with side holes, Ash Split Tip with side holes, Opti-flow dual 
lumen staggered tip with side holes) did not show hemodynamic or catheter survival 
advantage for any one catheter.(47) The plethora of multiple side hole designs on the 
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market reflects the belief that backup inflow is necessary in the case of obstruction. 
However, side holes can also cause thrombosis due the irregularity of their cut surfaces. 
In a recent comparison of two similar chronic dialysis catheters with and without side 
holes, Tal et al. demonstrated reduced bacteremia in the non side hole catheters, and 
attributed the result to reduced thrombus formation at the catheter tip.(48) Mareels et al 
presented a hemodynamic computer model demonstrating that in a multiple side hole 
catheter design, the first available hole is primarily employed. The distal holes appeared 
to comprise a low flow zone, suggesting an increased clotting risk.(49) There is also 
evidence that side holes can prevent locking solution from reaching the area between the 
side hole and catheter tip, precipitating clot formation at the tip.(50, 51) Clots may 
become firmly anchored to the walls around side holes, presenting a difficult to manage 
situation.  
A common drawback of many of the current catheter designs is high levels of 
recirculation upon lumen reversal, leading to subsequent flow failure. Reversal of the 
lumens in long-term dialysis catheters is usually performed to correct inadequate inflow, 
where the inflow through the arterial lumen is inadequate.(8) However, reversal of flow 
also leads to the undesirable effect of recirculation, whereby dialyzed blood exiting from 
one lumen directly enters the other lumen, bypassing systemic circulation. Recirculation 
of blood during dialysis reduces treatment efficiency and can lead to adverse health 
outcomes.(52, 53) 
A more recent catheter designed to address the problem of recirculation is the Tal 
Palindrome catheter. In this design, the arterial and venous tracts have the same length. 
While inflow occurs through the side slot and the most proximal portion of the end hole, 
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outflow occurs as a jet directed away from the catheter tip. This design was found to 
prevent recirculation in a swine model.(54) Kakkos et al recently demonstrated improved 
patency and reduced re-interventions with the Palindrome design compared to the split tip 
design.(55) Catheter patency was significantly higher in the Palindrome Ruby than in the 
Bard Bioblock.  Primary-assisted patency was significantly reduced with the BioBloc 
(71% and 61% at 90 and 180 days, respectively) compared with the Palindrome Ruby 




A catheter’s anti-thrombogenic properties are important for longevity, considering 
that thrombus formation begin as early as 24 hours after insertion.(56) Thrombosis and 
fibrin sheath can lead to inadequate hemodialysis by disrupting flow. Catheter exchange 
or fibrin sheath stripping can improve flow, but also introduce further risk for future 
complications.(57) The continuing development of catheter biomaterials, coatings, and 
tip designs reflects the need for better durability, as the current median dwelling time is 
little more than two months. The majority of unplanned catheter removals are due to 
infection and poor function.(58)  Poor function is generally related to flow problems that 
account for over half of these removals, with 76% of cases exhibiting fibrin sheath 
formation.(58, 59)  
In addition to causing flow problems, catheter thrombosis and fibrin sheath 
formation have also been implicated in the high rates of catheter-related infection seen in 
dialysis patients. Infections can be introduced into catheters extraluminally via skin or 
 14
intraluminally via the catheter hub. Bacteria can move through the skin insertion site 
along dermal tunnel and reach the tip of the catheter.(60) Fibrin sheath can exacerbate 
bacterial colonization by providing a habitable environment. In dialysis patients who are 
already immunocompromised, bacteria can become trapped in a within the fibronectin 
coating, rendering them inaccessible to immune cells.(31, 39, 61-63) Bacteria can also 
adhere to the catheter material itself, forming a protective glycocalix biofilm.(31, 63) The 
combination of breaking the skin barrier to insert a catheter, exposure to contaminants, 
and formation of pathogen-trapping fibrin sheaths can cause appreciable bacteremia risk, 
translating to up to three-fold relative mortality risk.(1, 19) New catheter design and 
coatings are often emphasized for their effects on reducing fibrin sheath formation and 




Central venous stenosis is a significant complication faced by patients who 
require chronic vascular access. The large-diameter hemodialysis catheters in use today 
are capable of delivering blood flow rates up to 450 cc/minute, creating hemodynamic 
stress that may play a significant role in the growing incidence of central venous 
stenosis.(64, 65) Since detection can be an issue, especially in asymptomatic patients 
with no indication for venograms, various studies report a wide range of central venous 
stenosis prevalence rates ranging from 16% to 41% in chronic hemodialysis patients.(64, 
66-68) The rate of venous stenosis also depends on catheter dwelling time, history of 
previous catheter insertion, and insertion site. Various studies show an incidence of 42% 
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to 50% subclavian stenosis compared with only 0% to 10% internal jugular stenosis.(30, 
69) Right-sided internal jugular venous catheters are also less likely to cause stenosis 
than left-sided catheters, due to the left brachiocephalic vein’s more tortuous course and a 
higher frequency of head motion-related movement with left-sided catheters.(4, 64) In 
fact, the NKF-K/DOQI guidelines recommend that the subclavian vein should be avoided 
in chronic renal failure patients who may require permanent vascular access.(6) 
Nonetheless, subclavian catheters may have a lower risk for infection and are more 
comfortable for the patient, and are often used for acute renal failure when hemodialysis 
is temporary. 
The pathogenesis of vascular stenosis can be similar to that of thrombosis, 
precipitated by trauma at sites where the catheter has contact with the vessel wall, 
especially where the vessel bends or when the cardiac cycle causes motion.(69) Physical 
damage from turbulence and trauma can result in platelet activation, thrombin generation, 
and ultimately an inflammatory response. More specific to the central veins, 
extravascular forces from surrounding structures may also contribute to development of 
venous stenosis. As the subclavian vein passes through the thoracic outlet, it can be 
affected by the clavicle, the subclavius and anterior scalene muscles, the first rib, and the 
subclavian artery. As the left brachiocephalic vein crosses the chest to merge with the 
right brachiocephalic vein, it must pass the great vessels, sternum, infrahyoid muscles, 
thymic remnants, and trachea. More proximally, the first rib and sternal border are near 
the origin of the superior vena cava. These potential extrinsic forces can accelerate the 
reactive and inflammatory processes within the vessel wall that ultimately lead to stenosis 
and occlusion.  
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Patients with central venous stenosis may be asymptomatic, or may present with 
head and arm edema mimicking cellulitis, pain, dysphagia, and venous varicosities.(65) 
Obstruction of the subclavian vein is associated with edema and venous hypertension of 
the ipsilateral arm and breast, while brachiocephalic vein stenosis also affects the face. 
Bilateral brachiocephalic vein obstruction or superior vena cava obstruction results in 
superior vena cava syndrome, characterized by edema of both arms, the face and neck, 
and development of dilated superficial collateral veins over the chest and neck. This 
condition requires intervention with surgery, angioplasty, or stenting, as it can become 
life-threatening if soft tissue edema of the neck leads to airway compression. Other 
complications of central venous stenosis include venous thrombosis, infections, 
inadequate dialysis, impaired arteriovenous fistula maturation, and decreased fistula and 
graft patency rate.(70) With a decrease in blood flow caused by the stenosis, subsequent 
recirculation via the vascular access may result in inadequate dialysis. 
In symptomatic cases, percutaneous and surgical solutions offer symptomatic 
benefit but recurrence is common in the chronic hemodialysis patient with compromised 
vascular access.(65, 66) Patients with hemodialysis access are much more likely to 
become symptomatic than nondialysis patients who have central venous stenosis (70% 
versus 10%). The presence of implantable pacemakers and defibrillators can raise these 
rates even higher, as they are well-known to cause vessel damage.(65) Percutaneous 
transluminal angioplasty for central venous stenosis is safe and effective, with 1-year 
patency rates ranging from 12% to 43%.(71, 72) Endovascular stent deployment is 
indicated if angioplasty alone leaves more than 50% residual stenosis, or if distal flow 
remains compromised with subsequent persistence of collateral flow. Primary stenting 
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could also be performed for select lesions to prevent early restenosis. However, the 
benefit of stents with angioplasty over angioplasty alone is still debated. Stents also suffer 
a high rate of restenosis secondary to inflammatory intimal reactions, with approximately 
25% patency rate at 1 year.(64) Surgical techniques such as internal jugular to axillary 
vein transposition, axillary-internal jugular vein bypass grafting, or right atrial bypass 
grafting can be performed, but these procedures are associated with greater morbidity and 
are therefore reserved for cases refractory to percutaneous intervention.(4) 
 
Role of fibrin sheaths 
 
Vessel trauma induced by procedures to correct catheter malfunction may also 
accelerate and exacerbate the development of central venous stenosis. Reasons for 
catheter malfunction include poor positioning or kinking, and obstructive thrombus or 
fibrin sheath formation. Fibrin sheath formation is a common cause of late catheter 
failures: 76% of catheters with poor function exhibit fibrin sheaths, with overall 
incidence cited at 42-100%.(10, 59) Fibrin sheaths usually originate at the site of catheter 
insertion or the subcutaneous cuff, migrating overtime down the length of the catheter 
and resulting in catheter dysfunction or other complications such as thrombosis or 
infection.  Fibrin sheath formation can start as early as 1 day after catheterization and 
encase the catheter by 5–7 days, and the length of the fibrin sleeve composed of smooth 
muscles can extend variable lengths, sometimes as far as the superior vena cava. In 
addition to physical obstruction, fibrin sheaths are also associated with venous 
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thrombosis and can harbor bacterial colonies that increase the rate of infection, 
significantly decreasing the longevity of the catheter. 
The first-line therapy for these malfunctioning catheters include non-invasive 
procedures such as positional maneuvers, port reversal, and thrombolytic instillation 
through the catheter.(73) Continuous infusion of lytic enzymes over 2-4-hours is standard 
therapy. Another, more economical option is to instill a much smaller amount of tissue 
plasminogen activator combined with heparin overnight.(73) If these procedures do not 
improve catheter performance, invasive approaches are indicated. For catheters still 
refractory, the physician may elect to perform over-the-wire catheter exchange without 
further imaging. Alternatively, venography can be performed to visualize catheter 
position and evaluate fibrin or thrombotic obstruction. If a fibrin sheath is visualized, 
both balloon disruption of the fibrin sheath and catheter exchange procedures are 
routinely utilized to restore flow.(74-78)   
 
Fibrin sheath disruption and catheter exchange 
 
There two main methods of fibrin sheath disruption. One type of procedure 
requires a femoral puncture, through which a snare is advanced and looped onto the 
exterior of the catheter, tightened, and pulled cephalad off the catheter tip to strip off the 
fibrin sheath. Dual lumen catheters may be stripped independently. An intra-luminal 
guidewire can facilitate additional stripping passes, and the number of passes can be quite 
variable from case to case.(79) Alternatively, a more definitive procedure involves 
balloon disruption of the fibrin sheath followed by catheter exchange. The 
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malfunctioning catheter is first removed over a stiff guidewire inserted through the lumen. 
An 8- to 12-mm-diameter angioplasty balloon catheter is then advanced over the 
guidewire and several inflations with back and forth motions within the vein are 
performed to disrupt the fibrin sheath along the entire length of the access vein. After 
confirmation of adequate aspiration and forward flow, a new catheter can then be placed 
over the guidewire.(59) 
Reported outcomes following fibrin sheath stripping vary significantly in the 
literature, perhaps as a result of its dependency on operator experience as well as 
differences in underlying patient population. The overall median duration of primary 
patency after the first snare stripping procedure ranges from 9 to 135 days. Technical 
success rates are high (90-100%) and complication rates low (0-5%) with both types of 
fibrin sheath disruption procedures.(74, 76, 77, 79-83) Gray et al found a mean 32 days 
of additional central dialysis catheter function after snare stripping procedures that did 
not differ significantly from thrombolytic therapy.(79) A study comparing snare fibrin 
sheath stripping and balloon disruption of fibrin sheath showed no statistically significant 
difference in cumulative patency rates or median duration of function—135 days with 
stripping and 75 days with balloon disruption.(77) However, in a recent randomized 
study, Oliver et al found a median time to dysfunction of 373 days with angioplasty 
balloon disruption, though not significantly higher than patients who did not undergo 
sheath disruption.(83)  
Over-the-wire catheter exchange is the other most commonly performed 
procedure to treat failed hemodialysis catheters with or without fibrin sheaths. It is an 
alternative to catheter removal and de novo catheter replacement at a different site. A 
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hydrophilic guidewire is first introduced through the catheter lumen in order to preserve 
access, and the catheter can be removed following blunt dissection of the tunnel cuff. 
Finally, a new hemodialysis catheter of the same size is inserted over the guidewire. 
Like fibrin sheath stripping, catheter exchange procedures are associated with 
technical success approaching 100% and low complication rates less than 10%.(77, 82, 
84, 85) Duszak et al demonstrated that catheter exchange provides similar catheter 
longevity and mean duration of function as de novo catheter placement: 30% and 35% at 
12 months, respectively.(85) Overall median duration of primary patency following 
catheter exchange ranges from 40 to 85 days, and cumulative patency at 6 months is 30-
40%.(77, 82, 84, 85) 
 
Complications of fibrin sheath disruption and catheter exchange 
 
Previous studies comparing outcomes following fibrin sheath stripping and 
catheter exchange examine catheter patency rates and short-term complications such as 
infection, rarely with long term follow up beyond 6 to 12 months.(74, 75, 77, 83, 86) 
There are even fewer studies directly comparing disruption of fibrin sheath with 
percutaneous angioplasty balloon versus catheter exchange, and none have found 
significant differences in outcome between the two procedures.  In a retrospective study, 
D’Othee et al found an immediate technical success rate of 100% and no complications 
with both procedures. Cumulative catheter patency rates with balloon disruption and 
catheter exchange were not significantly different at 6 months (39% and 28%, 
respectively). Median duration of patency was also similar at 75 days and 60 days, 
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respectively. Oliver et al’s prospective study found much longer, but similar, median 
durations of patency between the two procedures: 373 for balloon disruption and 97.5 
days for catheter exchange (P=0.22).   
While no complications where reported in either study, both studies have small 
sample size and lack long-term follow-up. The D’Othee study only includes 33 exchange 
and 15 balloon disruption procedures followed over 6 months, and the Oliver study 
includes 12 exchange and 18 balloon disruption procedures followed for a minimum of 6 
months. Embolization of the disrupted fibrin sheath is a theoretical immediate 
complication. Based on the pathogenesis of central venous stenosis, we hypothesize that 
vessel trauma caused by the fibrin sheath disruption procedure and subsequent 
inflammatory response can lead to central venous stenosis as a long-term complication 
with significant morbidity.  
The clinical link between the mechanical trauma induced by these procedures and 
the subsequent development of central venous stenosis is not well-explored. To our 
knowledge, the current study is the first one designed to evaluate late-onset central 
venous stenosis development after balloon disruption and over the wire catheter exchange. 
When central venous hemodialysis catheter dysfunction occurs in our practice, some 
physicians elect to perform a venogram followed by balloon disruption of fibrin sheath 
while others elect to do a catheter exchange over the wire. We also have an extensive 
database of long-term follow-up. Our study compares central venous stenosis and number 
of subsequent catheters exchange procedures in hemodialysis patients with 
malfunctioning catheters who undergo balloon disruption of fibrin sheath and those who 
receive a catheter exchange. 
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Statement of purpose 
 
 
To compare the rates of central venous stenosis in patients undergoing 
hemodialysis who underwent disruption of fibrin sheath with percutaneous transluminal 
angioplasty balloons and those who underwent over the wire catheter exchange. 
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Materials and methods  
 
Interventional radiology procedures were performed by experienced radiologists 
at Yale New Haven Hospital. All data collection, reconciliation, and statistical analyses 




This study is a retrospective review of patients who underwent balloon disruption 
of fibrin sheath with percutaneous transluminal angioplasty balloons and over the wire 
catheter exchange procedures in the past ten years. All data were obtained from a 
computerized databases and hospital medical records. Approval from the Human 
Investigations Committee was obtained for this study. The study includes 209 balloon 
disruption of fibrin sheath and 1,304 catheter exchange procedures performed at a large 
university hospital over a ten year period from August 1998 to August 2008.  
A database was constructed consisting of all visit information for hemodialysis 
patients who underwent balloon disruption and catheter exchange procedures in the past 
ten years. All data were retrieved from the institution’s radiology database. Indications 
for these procedures include catheter malfunction, infection, obstruction, and fibrin 
sheath formation, but were not consistently available. During exchange for catheter 
dysfunction, some repositioning often occurs. Available corresponding radiology reports 
for each patient were used to cross-check results and to identify patients who had 
subsequent central venous stenosis. Based on radiology report findings, significant CVS 
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was documented as stenosis of 50% or more. Data were also collected on patient age, sex, 
date of procedure, site of catheter placement, and diagnosis. Finally, hospital records 
were reviewed to determine discharge status, including time and cause of death, for 
patients in the study.  
 
Description of procedures 
 
At our institution, over-the-wire catheter exchange and balloon disruption of 
fibrin sheath stripping are routinely performed to restore flow to malfunctioning catheters, 
defined as those with flows less than 300 mL/min. All procedures included in the study 
were performed by an experienced interventional radiologist in the interventional 
radiology suite. Each radiologist has a personal preference for either catheter exchange or 
balloon disruption, choosing to perform one on a regular basis.  
Catheter exchange was performed in the standard manner, under local anesthesia 
over a guidewire. The catheters were bluntly dissected from the tunnel and retracted to 
the brachiocephalic vein. In some patients, injection of contrast was performed with 
digital subtraction chest imaging to detect the presence of a fibrin sheath or thrombus. In 
patients with clinical signs of infection, catheters were removed and the tip was sent for 
culture and sensitivity. A new catheter was then inserted over a 0.035-inch guide wire 
and advanced under fluoroscopic guidance. Over the years, various brands of chronic 
tunneled hemodialysis catheters were used. 
For radiologists who prefer to perform balloon disruption of fibrin sheath, the 
procedure of choice at our institution is balloon angioplasty over guidewire. An 8-12 mm 
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wide, 4 cm long angioplasty balloon (Bard Inc. Tempe, AZ) was inserted over a 
guidewire and inflated. Under fluoroscopic guidance, the fibrin sheath was disrupted with 
back-and-forth motions of the balloon in the region of the proximal right atrium to the 
confluence of the brachiocephalic vein. The balloon was then removed over a guidewire, 
and a new catheter was partially inserted. Contrast was then injected for confirmation of 
sheath disruption, and the catheter was fully advanced under fluoroscopic guidance to the 
proper position. (Figure 1) 
 
Figure 1: Percutaneous transluminal balloon angioplasty performed over guidewire.   
A: After the catheter has been pulled back over guidewire (catheter tip indicated by white 
arrow), a gentle injection of contrast outlines the fibrin sheath (black arrow). B: A 
balloon catheter (black arrow) is advanced into the vein. Via back and forth motions 
under fluoroscopic guidance, the fibrin sheath is disrupted. C: After the procedure, 
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venogram shows that the vein is patent and the fibrin sheath has disappeared. The black 




A χ2 test was used to compare the proportions of patients who develop central 
venous stenosis after balloon disruption versus catheter exchange procedures. Patients 
who underwent both balloon disruption and catheter exchange procedures were 
considered in the balloon disruption group. A T-test was used to compare the time to 
central venous stenosis development, determined from the date of the first balloon 
disruption or catheter exchange procedure. Finally, a χ2 test was also used to determine 
differences in mortality from all causes between the two groups. Differences were 





The study’s 209 balloon disruption and 1,304 catheter exchange procedures 
represent 127 and 626 patients, respectively. There were 79 females and 48 males in the 
balloon disruption group, and 332 females and 294 males in the catheter exchange group. 
The average ages are 62.0 ± 1.2 (standard error of the mean) and 60.5 ± 0.5 in the balloon 
disruption group and catheter exchange group, respectively (Table 1). Mortality by the 
end of the study was not significantly different between the two groups, with 15.0% in 
the balloon disruption group and 12.3% in the catheter exchange group (P=0.41). 
 
Table 1: Demographic characteristics of the study groups 
  Balloon Disruption Catheter Exchange 
Number of Patients 127 626 
Female : Male 79 :48 332 : 294 
Average Age 62.0 ± 1.2 60.5 ± 0.5 
 
 
Catheter placement at the time of central venous stenosis diagnosis was also 
recorded. The majority of catheters were placed in the right IJ in both the balloon 
disruption and catheter exchange groups (51% and 65%, respectively). There was no 
statistically significant difference between the two groups. When broken down by the 
presence of CVS, patients who did and did not exhibit CVS did not differ significantly in 
the rate of right IJ placement (Table 2). 
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Table 2: Central venous catheter placement at the time of central venous stenosis 
 
 % R IJ A % L IJ B % L SC C % R SC D 
Total Balloon Disruption 51% 35% 3% 11% 
     No CVS E 63% 26% 5% 5% 
     CVS 39% 44%  17% 
      
Total Catheter Exchange 65% 35%   
     No CVS 72% 28%   
     CVS 42% 58%   
          
χ2 tests: R IJ v. L IJ in patients with and without CVS 
     Balloon Disruption  P=0.17    
     Catheter Exchange P=0.06    
 
A R IJ: right internal jugular vein. B L IJ: left internal jugular vein. C L SC: left subclavian 
vein. D R SC: right subclavian vein. E CVS: central venous stenosis 
 
Within the balloon disruption group, 18/127 patients (14.2%) exhibited central 
venous stenosis after their procedure, versus 44/626 (7.0%) in the catheter exchange 
group (P<0.01, χ2 test). Time to central venous stenosis development after disruption or 
exchange was not significantly different between the two groups (1,371 ± 234 days for 
balloon disruption, 1,010 ± 145 for catheter exchange, P=0.20). The average number of 
catheter exchanges after a balloon disruption procedure was 2.76 ± 0.36, compared with 
2.02 ± 0.07 after a previous catheter exchange (P=0.04). Patients having 4 or more 
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subsequent exchanges were 25.2% in the balloon disruption group and 12.6% in the 
catheter exchange group (P<0.01, χ2 test).  (Table 3, Figure 2) The location of CVS was 
also analyzed. Within the balloon disruption group, superior vena cava stenosis was 
31.3% compared with 14.8% in the catheter exchange group, but the difference was not 
statistically significant. (Table 4)  
 











Number of Patients 127 626  
Patients with CVS A 18 (14.2%) 44 (7.0%) <0.01 
Days to CVS 1,371 ± 234 1,010 ± 145 0.20  
Mortality 19 (15.0%) 77 (12.3%) 0.41 
Average # Catheter Exchanges  
Following Procedure 
2.76 ± 0.36 2.02 ± 0.07 0.04 
Patients with >=4 exchanges 32 (25.2%) 79 (12.6%) <0.01 
 





Figure 2: Outcomes following balloon disruption and catheter exchange. CVS: central 
venous stenosis. 
 
Table 4: Location of central venous stenosis by procedure 
 
  SC A SC-BC B BC C BC-SVC D SVC E 
Balloon Disruption 0.0% 12.5% 43.8% 12.5% 31.3% 
Catheter Exchange 11.1% 14.8% 48.1% 11.1% 14.8% 
Combined 7.0% 14.0% 46.5% 11.6% 20.9% 
 
A SC: subclavian vein; B SC-BC: subclavian-brachiocephalic junction; C BC: 
brachiocephalic; D BC-SVC: brachiocephalic-superior vena cava junction; E SVC: 





Central venous stenosis occurring in the subclavian, brachiocephalic veins or 
superior vena cava is a significant problem in chronic hemodialysis patients. The 
incidence of central venous stenosis in central venous catheter patients ranges from 3–
50%, with internal jugular placement associated with significantly lower rates of 3-
10%.(30, 68, 69) Propagation of endothelial injury and neointimal hyperplasia result from 
prolonged central venous catheterization and arteriovenous shunts.(10, 66, 87) Aside 
from symptomatic manifestations such as arm or neck swelling, hemodialysis access 
failure due to decreased vessel patency and increased venous pressure can lead to 
significant morbidly and mortality.(68, 87, 88) Bilateral central vein stenosis or superior 
vena cava stenosis can lead to superior vena cava syndrome. Currently, endovascular 
interventions including angioplasty and stent placement are the mainstay of treatment. 
Multiple interventions are often required, and surgical bypass is an option. As a last resort, 
patients will forgo their existing hemodialysis access, and another access point would be 
established.(64, 70)  
Despite the host of complications that can arise from long term use of central 
venous catheters, their use has risen significantly from 13% of ESRD patients in 1995 to 
26% of ESRD patients by 2001.(2) The most common and serious problems associated 
with long-term catheterization include thrombosis, stenosis, and infection.(4, 5) Fibrin 
sheath formation can increase the risk of bacteremia by providing a favorable site for 
microorganism colonization.(4, 31, 63, 89) Based on the 300 ml/min minimum flow 
requirement of the K/DOQI guidelines, 5 to 13% of patients will require additional 
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procedures to treat dysfunction.(58, 62, 90-92) For malfunctioning catheters refractory to 
repositioning, flow reversal, saline flushes, or thrombolytic installation, mechanical 
methods such as balloon disruption of fibrin sheath and catheter exchange are then 
employed.(4, 8, 20, 22, 81, 84) When fibrin sheath formation is discovered to be the 
cause of catheter malfunction, sheath disruption can be performed percutaneously via a 
gooseneck snare, J-tipped guide wire, pig-tail catheter, or balloon catheter.(8, 73, 75, 76, 
78) Alternatively, catheter exchange over guidewire can be performed, though not always 
accompanied by a search for etiology. While several previous studies have shown that 
catheter patency rates do not differ significantly between these procedures, we examine 
the long term outcome of the patient.(74-76, 78) 
In studies that have compared clinical outcomes after fibrin sheath disruption and 
catheter exchange, the focus has been on catheter patency and hemodialysis adequacy. 
Earlier studies provide a wide range for the mean primary catheter patency after various 
methods of fibrin sheath disruption, between one and four months.(74-76, 78) There is 
some evidence that catheters treated by catheter exchange are significantly more likely to 
remain patent for up to four months than those treated by fibrin sheath disruption.(75) 
However, in a retrospective study comparing outcomes after over-the-wire catheter 
exchange, fibrin sheath stripping from a femoral vein approach, and balloon disruption of 
fibrin sheath, the authors found equivalence in immediate technical success, complication 
rates, and mean patency rates.(77) Oliver et al. show in a pilot study that median time to 
repeat catheter exchange and repeat dysfunction were not significantly different between 
catheter exchange and catheter exchange with balloon disruption of fibrin sheath.(93) 
They did find that balloon disruption modestly improves blood flow and urea clearance.  
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In this study, we aim to compare the occurrence of late-onset central venous 
stenosis after balloon disruption of fibrin sheath and catheter exchange. In our 
retrospective series, we demonstrate a possible association between central venous 
stenosis and balloon disruption of fibrin sheath. The number of subsequent catheters 
placed was also higher following balloon disruption compared with catheter exchange.  
Due to the retrospective nature of the study, however, there are underlying 
differences in general health and vascular status between the two groups that make it 
difficult to draw definitive conclusions about outcome differences. Data regarding co-
morbidities that can influence outcomes as well as the symptoms of central venous 
stenosis were only available from radiology reports and therefore were neither consistent 
nor reliable. Most cases of CVS were diagnosed during fistulography and documented as 
stenosis of 50% or more, decided by the performing radiologist at the time. It was also 
not possible to determine the length of catheter use for the whole ten-year duration of 
study because data regarding catheter removal was not reliably documented and could not 
be reliably analyzed due to the retrospective nature of this study. However, mortality is 
not significantly different between the two groups, suggesting similar baseline health. 
Another key underlying difference between the two experiment groups is physician 
decision. Even though most physicians prefer one of the two methods for the majority of 
their patients, they may also make individualized decisions based on patient presentation. 
It must also be emphasized that a major weakness of this study is that there is an 
unknown proportion of patients in the catheter exchange cohort who may have fibrin 
sheaths accounting for their catheter dysfunction. Venograms confirming the presence or 
absence of fibrin sheaths are not routinely performed in the exchange group. Therefore, 
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not all catheter exchanges necessarily represent incidences of fibrin sheath occurrence. 
As a result, it is possible that the fibrin sheath itself, and not the balloon disruption 
procedure, is the main cause of worse outcomes.  During the ten year period, there might 
have been instances of catheter exchange where a venogram was performed with the 
intent of stripping but no fibrin sheath was found. These severe limitations of this 
retrospective study can only be overcome with a prospective long term randomized 
clinical trial comparing over the wire exchange with balloon disruption.  
In summary, central venous stenosis remains a significant problem in chronic 
hemodialysis patients. This retrospective study suggests a possible correlation between 
balloon angioplasty for disruption of fibrin sheath and late onset of central venous 
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